VSE Capital Markets

Dr Reddys Laboratories Ltd

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE4,760.85 -39.60 (-0.82%)

PREV CLOSE (₹) 4,800.45

OPEN PRICE (₹) 4,826.85

BUY PRICE4,753.10(×15)

SELL PRICE 4,756.10(×1)

VOLUME 115,779

TODAY'S RANGE (₹)4,841.004,720.00

52 WK RANGE(₹)5,613.654,135.90

NSE4,749.75 -52.05 (-1.08%)

PREV CLOSE( ₹ ) 4,801.80

OPEN PRICE (₹) 4,801.05

BUY PRICE 4,749.05(×26)

SELL PRICE4,749.75(×23)

VOLUME 287,205

TODAY'S RANGE(₹) 4,844.454,718.00

52 WK RANGE (₹)5,614.604,135.00

Stock Summary

MARKET CAP (₹ CR)	79,879.01
P/E	48.42
BOOK VALUE (₹)	1,032.48
DIV (%)	500.00
MARKET LOT	1.00

EPS (TTM)	99.14
PRICE/BOOK	4.65
DIV YIELD.(%)	0.52
FACE VALUE (₹)	5.00
DELIVERABLES (%)	40.11

Background Information

Incorporation Year	1984
Registered Office	8-2-337 Road No 3,Banjara Hills Hyderabad,Telangana-500034
Telephone	91-40-49002900,
Fax	91-40-49002999
Chairman	K Satish Reddy
Managing Director
Company Secretary	Sandeep Poddar
Auditor	S R Batliboi & Associates LLP
Face Value	5
Market Lot	1
Listing	BSE,MSEI ,New York,NSE,
Registrar	Big Share Services Pvt Ltd 3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082

MF Holdings

Scheme Name	Hold(%)
SBI ETF Nifty 50	0.78
Aditya Birla SL Flexi Cap Fund	5.17
Mirae Asset Large Cap Fund	1.99
SBI ETF SENSEX	0.90
Nippon India Pharma Fund	9.36

News & Announcements

Date	News
19-Oct-2021	Dr Reddys receives USFDA approval for Lenalidomide Capsules
18-Oct-2021	Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
16-Oct-2021	Dr Reddys Laboratories launches Carmustine for Injection in US market
14-Oct-2021	Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Loss of Share Certificates

Share Holding

Peer Group

Sun Pharmaceuticals Industries Ltd 813.30 ( -1.70)	M.Cap (₹ in Cr) 198508.98
Cipla Ltd 905.60 ( -0.07)	M.Cap (₹ in Cr) 73098.95
Piramal Enterprises Ltd 2659.75 ( -3.19)	M.Cap (₹ in Cr) 65566.88
Cadila Healthcare Ltd 517.05 ( -1.81)	M.Cap (₹ in Cr) 53910.29
Torrent Pharmaceuticals Ltd 2978.90 ( -2.98)	M.Cap (₹ in Cr) 51959.00

3rd Floor,Fortune Tower,Sayajigunj, Vadodara 390020, Gujarat, India

Telephone: +91 265 2361534

Customer Care Number: +91 265 2361474

Customer Care Timings: Monday to Friday 8:30am to 6:15pm

Email Address: vse@vselindia.com / compliance@vselindia.com

Attention Investors:

"Prevent Unauthorized transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
KYC is one time exercise while dealing in securities market - once KYC is done through a SEBI registered intermediary (broker , DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

For any complaints pertaining to securities broking please write to compliance@vselindia.com, for DP related to dp@vselindia.com. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed.